ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
San Diego–based Debut Biotechnology has secured exclusive licenses to two inventions from the University of California, Irvine, that the company says enable continuous manufacturing of drugs, alcoholic beverages, and cannabinoids. According to Debut, the technology is based on enzyme cartridges and enables the synthesis of high-value products to move from batch to continuous processes. The shift can cut the cost and time of production and save space, water, and energy, the firm says.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X